Item 8.01 Other Events.
On January 4, 2021, Harpoon Therapeutics, Inc. (the "Company") issued a press
release announcing that the first patient has been dosed with HPN328, a delta
like ligand 3 ("DLL3")-targeting TriTAC®, in a Phase 1/2 clinical trial as an
investigational treatment of small cell lung cancer and other tumors associated
with DLL3 expression. A copy of the Company's press release is attached hereto
as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release dated January 4, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses